PPH Legal Blog

Primary Pulmonary Hypertension (PPH) is most frequently diagnosed during routine testing for the causes of high blood pressure. PPH may go undetected for years. Often, it is up to the patient to tell their doctor they took diet drugs, even if it was decades ago.
Kendall Lewis took the diet drug Adapex for weight loss in […]

[Read more →]

The new black box warning that is to be placed on the label for Avandia indicating that taking the drug may actually increase one’s risk for heart attack and heart failure as dictated by the FDA is much less stringent than the warning being placed on the label for Avandia sold in Europe and Canada.
The […]

[Read more →]

A new method for diagnosing primary pulmonary hypertension has been developed which is much less invasive and allows for earlier diagnosis.
The current method of diagnosis, cardiac catheterization, is invasive and involves inserting a flexible tube into the jugular vein which is then sent through the vein to the right side of the heart to have […]

[Read more →]

According to findings by the Senate Finance Committee, GlaxoSmithKline was so concerned about the negative feelings of one doctor that they repeatedly and concertedly tried to quiet his opinions via intimidation.
The Senate reports opens a rare window into the relatively little known pharmaceutical practice of trying to influence how leading physicians feel about a drug. If the […]

[Read more →]

Yesterday the FDA announced the new “black box” wording for Avandia. The new label has upset many patient advocate groups as it is not a particularly strongly worded new label. They are calling it the latest incidence of the FDA turning a blind eye towards Avandia’s problems.
Avandia’s heart attack risk has been known, apparently, to […]

[Read more →]